{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:59:10Z","timestamp":1780901950284,"version":"3.54.1"},"reference-count":51,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/17425255.2026.2643444","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:16:27Z","timestamp":1773926187000},"page":"385-397","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Predicting the potential for organic cation transporter 1-mediated drug\u2013drug interactions with fenoterol by amitriptyline, fluoxetine, selegiline, metformin, and verapamil"],"prefix":"10.1080","volume":"22","author":[{"given":"Alex","family":"Williams","sequence":"first","affiliation":[{"name":"Cyprotex Discovery Limited (An Evotec Company)","place":["Macclesfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorcha","family":"Mackle","sequence":"additional","affiliation":[{"name":"Cyprotex Discovery Limited (An Evotec Company)","place":["Macclesfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sakinyte","sequence":"additional","affiliation":[{"name":"Cyprotex Discovery Limited (An Evotec Company)","place":["Macclesfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Sholl","sequence":"additional","affiliation":[{"name":"Cyprotex Discovery Ltd (An Evotec Company)","place":["Macclesfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"Cyprotex Discovery Ltd (An Evotec Company)","place":["Macclesfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Adshead","sequence":"additional","affiliation":[{"name":"Cyprotex Discovery Ltd (An Evotec Company)","place":["Macclesfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Elsby","sequence":"additional","affiliation":[{"name":"Cyprotex Discovery Limited (An Evotec Company)","place":["Macclesfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1985.tb03409.x"},{"issue":"5","key":"e_1_3_5_4_1","first-page":"334","article-title":"Fenoterol solution via nebuliser\u2013optimum dosage","volume":"71","author":"Harries AV","year":"1987","unstructured":"Harries AV, Laroche CM, Britton MG. Fenoterol solution via nebuliser\u2013optimum dosage. Eur J Respir Dis. 1987;71(5):334\u2013338.","journal-title":"Eur J Respir Dis"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.2.137"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.088781"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.812"},{"key":"e_1_3_5_8_1","unstructured":"US Food and Drug Administration (FDA) [Internet]. Final guidance for industry: in vitro drug interaction studies \u2013 cytochrome P450 enzyme- and transporter-mediated drug interactions. Maryland (USA); 2020 [cited 2022 Mar 9]. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM581965.pdf"},{"key":"e_1_3_5_9_1","unstructured":"European Medcines Agency [Internet]. Amsterdam the Netherlands. Guideline on the investigation of drug interactions. 2013 [cited 2017 May 2]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf"},{"key":"e_1_3_5_10_1","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) [Internet]. ICH harmonised guideline drug interactions studies M12. Geneva Switzerland; 2024 [cited 2025 Sep 18]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1112"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.941"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1986.tb11151.x"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2019.1670804"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14121575"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1134472"},{"key":"e_1_3_5_17_1","unstructured":"Selegiline hydrochloride (Eldepryl\u00ae) US FDA drug label. Somerset Pharma Inc; 2008."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.688950"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055095"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100074"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.317"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.1777"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.357"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.163"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.066795"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.083832"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2022.2132932"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1060"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8003152"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.09013fp"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.152"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733020-00002"},{"key":"e_1_3_5_34_1","unstructured":"Metformin hydrochloride (Glucophage\u00ae) US FDA drug label. Merck Sant\u00e9 S.A.S. Germany; 2018."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03226.x"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s12160200"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198938010-00003"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-018-9597-6"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199308000-00002"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/11534750-000000000-00000"},{"key":"e_1_3_5_41_1","unstructured":"Verapamil hydrochloride (Calan\u00ae) US FDA drug label. Pfizer Inc; 2017."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05038.x"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.3c00143"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2012.01.034"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.06.019"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101974"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)08235-2"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00583-z"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.1999.tb00006.x"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259409043222"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/026520499288825"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)39589-3"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.648388"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2643444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:21:16Z","timestamp":1780899676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2026.2643444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/17425255.2026.2643444"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2026.2643444","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}